



**Millendo Therapeutics to Present at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference**

**ANN ARBOR, Mich., January 3, 2018** – [Millendo Therapeutics, Inc.](http://www.millendo.com), a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:30 AM PT. The presentation will contain a business overview and pipeline update following Millendo's recent acquisition of Alizé Pharma SAS and subsequent expansion into Prader-Willi syndrome.

**About Millendo Therapeutics, Inc.**

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing's syndrome. [www.millendo.com](http://www.millendo.com)

###

**Media Contact:**

Cammy Duong  
MacDougall Biomedical Communications  
781-591-3443  
[cduong@macbiocom.com](mailto:cduong@macbiocom.com)